HomeCompareEJFAW vs ABBV

EJFAW vs ABBV: Dividend Comparison 2026

EJFAW yields 555.56% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EJFAW wins by $139998.74M in total portfolio value
10 years
EJFAW
EJFAW
● Live price
555.56%
Share price
$0.36
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$139998.84M
Annual income
$103,389,823,141.26
Full EJFAW calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — EJFAW vs ABBV

📍 EJFAW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEJFAWABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EJFAW + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
EJFAW pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EJFAW
Annual income on $10K today (after 15% tax)
$47,222.22/yr
After 10yr DRIP, annual income (after tax)
$87,881,349,670.07/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, EJFAW beats the other by $87,881,328,614.07/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EJFAW + ABBV for your $10,000?

EJFAW: 50%ABBV: 50%
100% ABBV50/50100% EJFAW
Portfolio after 10yr
$69999.47M
Annual income
$51,694,923,956.51/yr
Blended yield
73.85%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

EJFAW
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EJFAW buys
0
ABBV buys
0
No recent congressional trades found for EJFAW or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEJFAWABBV
Forward yield555.56%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$139998.84M$102.3K
Annual income after 10y$103,389,823,141.26$24,771.77
Total dividends collected$136892.42M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: EJFAW vs ABBV ($10,000, DRIP)

YearEJFAW PortfolioEJFAW Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$66,256$55,555.56$11,550$430.00+$54.7KEJFAW
2$414,899$344,006.00$13,472$627.96+$401.4KEJFAW
3$2,457,216$2,013,273.57$15,906$926.08+$2.44MEJFAW
4$13,772,667$11,143,445.47$19,071$1,382.55+$13.75MEJFAW
5$73,109,539$58,372,785.46$23,302$2,095.81+$73.09MEJFAW
6$367,816,599$289,589,392.61$29,150$3,237.93+$367.79MEJFAW
7$1,755,184,486$1,361,620,725.22$37,536$5,121.41+$1755.15MEJFAW
8$7,950,495,654$6,072,448,253.97$50,079$8,338.38+$7950.45MEJFAW
9$34,214,035,108$25,707,004,758.47$69,753$14,065.80+$34213.97MEJFAW
10$139,998,840,707$103,389,823,141.26$102,337$24,771.77+$139998.74MEJFAW

EJFAW vs ABBV: Complete Analysis 2026

EJFAWStock

EJF Acquisition Corp. is a blank check company. The company was incorporated in 2020 and is based in Arlington, Virginia.

Full EJFAW Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this EJFAW vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EJFAW vs SCHDEJFAW vs JEPIEJFAW vs OEJFAW vs KOEJFAW vs MAINEJFAW vs JNJEJFAW vs MRKEJFAW vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.